At Interface Bio, we are building a drug company at the frontier of innovation through the development of peptide therapeutics for immunotherapy.
At Interface Bio, we are building a drug company at the frontier of innovation through the development of peptide therapeutics for immunotherapy.
Peptide therapeutics are the hottest modality in pharma today given they combine the potency of antibodies with the tissue access of small molecules. Despite this potential, the full therapeutic power of peptides has not yet been because of their fatal instability. By synergizing AI, biology, and peptide chemistry, Interface Bio's platform develops next generation, hyper-stable peptide therapeutics for a wide range of indications.
Peptide therapeutics are the hottest modality in pharma today given they combine the potency of antibodies with the tissue access of small molecules. Despite this potential, the full therapeutic power of peptides has not yet been because of their fatal instability. By synergizing AI, biology, and peptide chemistry, Interface Bio's platform develops next generation, hyper-stable peptide therapeutics for a wide range of indications.
At Interface Bio, we are building a drug company at the frontier of innovation through the development of peptide therapeutics for immunotherapy.
Peptide therapeutics are the hottest modality in pharma today given they combine the potency of antibodies with the tissue access of small molecules. Despite this potential, the full therapeutic power of peptides has not yet been because of their fatal instability. By synergizing AI, biology, and peptide chemistry, Interface Bio's platform develops next generation, hyper-stable peptide therapeutics for a wide range of indications.
Integrating unprecedented stability, potency, and safety for breakthrough therapeutics.
Blockbuster peptide therapeutics such as Ozempic took 40 years to develop because of the inherent instability of the native peptide. Our proprietary technology alleviates the current bottlenecks by creating hyper-stable, potent, and nontoxic next-generation peptide therapeutics.
Blockbuster peptide therapeutics such as Ozempic took 40 years to develop because of the inherent instability of the native peptide. Our proprietary technology alleviates the current bottlenecks by creating hyper-stable, potent, and nontoxic next-generation peptide therapeutics.
Integrating unprecedented stability, potency, and safety for breakthrough therapeutics.
Blockbuster peptide therapeutics such as Ozempic took 40 years to develop because of the inherent instability of the native peptide. Our proprietary technology alleviates the current bottlenecks by creating hyper-stable, potent, and nontoxic next-generation peptide therapeutics.
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
02
Screen
After production of our high-value sactipeptide libraries, we use targeted screens to identify assets with high potency against previously intractable targets.
02
Screen
After production of our high-value sactipeptide libraries, we use targeted screens to identify assets with high potency against previously intractable targets.
03
Optimize
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
03
Optimize
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
04
Validate
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
04
Validate
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
02
Screen
03
Optimize
04
Validate
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
02
Screen
03
Optimize
04
Validate
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
02
Screen
03
Optimize
04
Validate
01
Search and Build
Sactipeptides are an extremely rare and valuable class of peptides due to their unique and hyper-stable thioether bridge. We use our proprietary AI modeling system to characterize novel sactipeptides that have drug-like properties. This information is also used as training data to predict how thioether bridges can be engineered into human peptides to make them more stable for drug development.
02
Screen
03
Optimize
04
Validate
Get in Touch
Get in Touch
Reach out if you are interested in working with us or would like to learn more about how natural products could revolutionise the chemical space
Reach out if you are interested in working with us or would like to learn more about how natural products could revolutionise the chemical space
Get in Touch
Reach out if you are interested in working with us or would like to learn more about how natural products could revolutionise the chemical space
